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Percutaneous Intramyocardial Chemical Ablation: Preliminary
Results in the Treatment of Ventricular Tachycardia Model of Dogs
CAIYI LU, XUANLI LIU, CONGCUN HUANG, XUAN WEI, GUANGXIN JIA, SHUSEN MAO
From Air Force General Hospital, Beijing, China
LU ET AL.: Percutaneous Intramyocardial Chemical Ablation: Preliminary Results in the Treatment of Ventricular
Tachycardia Model of Dogs. Sustained ventricular tachycardia simulated by implanted subepicardial pacing
microelectrodes in 18 dogs was treated by a novel percutaneous intramyocardial chemical ablation with 100%
ethanol. The ablation catheter consists of a specially designed mapping catheter and a steerable chemical ablation
catheter. Ventricular tachycardia (VT) mapping and ablating manipulation was taken under the fluoroscopy in a
catheterization laboratory. Results: The success rate of chemical ablation was 100%. The induction rate of new VT
was 16.7% at 4 weeks after ablation. The acute response of VT to chemical ablation included: (1) the focus was
ablated completely within 3 seconds (73.3%), and (2) VT was intermittently stopped and then disappeared within 10
seconds (26.7%). The epicardium near the ablated focus changed into pale after ethanol injection. Four weeks later,
the border between lesion and normal tissue became indistinct. There were normal myocardial islands in chronic
fibrous lesion. Conclusions: (1) It is feasible by using percutaneous intramyocardial chemical ablation to treat
sustained VT. The success rate could get to 100% if VT focus is accurately mapped. (2) The ablating lesion can be
limited in myocardial layer if the amount of chemical agent is appropriately controlled. The epicardium and
endocardium near the lesion could be normal. (3) The induced VT after chemical ablation suggests the therapy may
have potential long-term proarrhythmic effect. (J HK Coll Cardiol 2001;9:119-125)
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Introduction
Ventricular tachyarrhythmia is one of the most
common cardiovascular disorders that influence human
health and life expectancy. Refractory ventricular
tachycardia (VT) causes nearly 500,000 sudden deaths
per year around the world. The present therapies for
malignant VT include the following:1-4
1.

2.

3.

4.

5.

Medication: Antiarrhythmic medication has long
been used as a main means in the treatment of
various VTs. But it is not a radical cure. It has
limited long term benefits. Certain agents may have
serious side effects such as fatal proarrhythmic
action.
ICD implantation: It is also not a radical cure. It
has operative complications and requires frequent
replacement in the limited years. In addition, it is
expensive for patients in developing countries.
Open heart surgery: It complicates with high
perioperative mortality, possible afteroperative
arrhythmia and expensive hospitalization.
Intracoronary chemical ablation: It causes harmful
artificial myocardial infarctions, has higher
probability of proarrhythmic action and fewer
indications.
Endomyocardial radiofrequency catheter ablation:
It is more suitable to the idiopathic VT than to other
ventricular tachyarrhythmias such as those
complicated with ischemic heart disease. In order
to explore a new interventional radical cure for
sustained VT, we tested the feasibility,
effectiveness and safety of the percutaneous
intramyocardial chemical ablation in experimental
VT model of dogs.

is an outer mapping catheter and the other is an inner
ablation catheter. The mapping catheter is 100
centimeters long and has one central lumen along its
axis and 2 electrodes with interelectrode distance of 5
millimeters (mm) at its tip. The proximal electrode is a
ring and the distal electrode is a cylinder containing a
coaxial hole of 2 mm in diameter. In addition, a steerable
wire is fixed at the inner wall with one end located
10 mm away from its tip. The ablation catheter is 120
centimeters long and has an inner lumen of 2 mm in
diameter. At its tip is installed a micro needle with an
outer diameter of 1.5 mm, an inner lumen of 1 mm in
diameter and a short inclined plane of 1 mm. The needle
is 5 mm long. Additionally, there are fine scales and
knocking apparatus at its tail part that are used to control
the needle length exceeding the tip electrode of the
mapping catheter. The total lumen volume of the needle
and the catheter stem is 1 ethanol milliliter. The flow
capacity of the ablation catheter is 230 ul/min ethanol
under 5 atmosphere pressure.
This study has been approved by the Ethic
Committee of Chinese Air Force General Hospital.
Mongrel dogs were provided by Chinese Military
Academy of Medical Science. The subepicardial VT
model has already been reported elsewhere.5 In briefly,
the dog is anaesthesed intravenously and ventilated by
Bird Brand ventilator. The heart is manifested by right
sternum incision and the pericardium is cut out carefully.
A microelectrode of 0.5 mm by 1.0 mm is implanted as
a pacing cathode in the subepicardium at the right
ventricular apex under the operative microscope. The
anode is a temporary needle inserted into the
subcutaneous tissue of a forelimb. If the heart could be
paced at 350 bpm by an appropriate diastolic threshold,
then the cathode wire is properly fixed. The dog is then
alive over 7 days for further ablation procedure after
the pericardial and thoracic cavities are closed.

Material and Methods
The design and the making of the chemical
ablation catheters
A special chemical catheter (Figure 1) is designed
to complete the following tasks: (1) remote
percutaneous manipulation in the heart; (2) precious
endomyocardial mapping; and (3) accurate chemical
ablation. Therefore the catheter is consisted with 2
different parts as shown in Figure 1. In briefly, one part
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Electrophysiological Mapping and Chemical
Ablation
Cardiac electrophsiological study and catheter
ablation manipulation were completed in a
catheterization laboratory with Philips DSA imagine
system. After regular catheterization preparation, two
5F quadripolar electrode catheters (USCI Co.,
interelectrode distance 5 mm) were inserted via left
femoral vein by Seldinger procedure to record the high

July 2001

J HK Coll Cardiol, Vol 9

LU ET AL.

Figure 1. The structure of the chemical catheter sets (see text for details). (1) intramural needle, (2)
cylinder electrode, (3) ring electrode, (4) mapping catheter, (5) ablation catheter.
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right atrium (HRA) and the His bundle electrograms
(HBE). Via right femoral vein, the chemical ablation
catheter is introduced through a long shelth and
positioned in right ventriculum. The surface
electrocardiograms of I, aVF, V5, intracardiac HRA,
HBE and the electrogram from the ablation catheter
were recorded simultaneously by a RECOR (Siemens
Co.). Standard cardiac electrophysiological studies were
conducted before chemical ablation, 30 minutes and 4
weeks after ablation, respectively.6,7
After basic electrophysiological study, the VT
was simulated by a cardiac programme stimulater
(UHS-1, Biotronik Co.) at a pacing rate of 350 bpm
and a volt of 2 times of diastolic threshold between the
implanted subepicardial cathode and the subcutaneous
needle anode. The mapping catheter was manipulated
to map the VT focus. After that, the catheter was slightly
pressed to make a stable contact between the cylinder
electrode and the endocardium. The catheter was
properly fixed and the electrogram was instantly
monitored. Then the chemical ablation catheter was
slowly screwed forward to pierce through the
endocardium. The puncture depth was controlled by the
tail scales. Then 2 ml ice saline solution with contrast
was injected to do a trial ablation (the contrast is used
to avoid possible intracoronary injection). If the VT
focus was responded to the trial ablation, another 2 ml
pure ethanol was injected at a speed of 200 ml/min. If
the VT was ended in 10 minutes, the procedure was
completed. Otherwise, more mappings and injections
were taken until ablation succeeded or more than 10
milliliter ethanol was injected. After the ablation
procedure, the dogs were still kept survival for another
4 weeks before an autopsy.

Data Management
Data is presented as mean±standard deviation
(M±SD). Student-t test is used to analysis the data and
P<0.05 is defined as a significant level.

Results
Subepicardial Ventricular Tachycardia Model
Altogether 18 dogs were used. Their weight was
18±3kg. Three of them were used to evaluate the
implanted electrode. The other 15 were used for
ablation. Three dogs among the 15 were killed after
acute ablation. The other 12 were alive for more than 4
weeks for further evaluation.
All 18 implanted electrodes can be paced
successfully. The pacing threshold was 0.9±0.7 volts at
the time of implantation and 1.2±0.5 volts just before
ablation procedure (P<0.01). The simulated VT was well
reproduced in 4 weeks.

Acute Response of VT Focus to Chemical
Ablation
Fifteen dogs with simulated VT were ablated with
total success rate of 100%. Eleven of them (11/15,
73.3%) were succeeded at the first ethanol injection and
VT was terminated within 3 seconds (Figure 2). The
other 4 (4/15, 26.7%) succeeded at the second or third
injection and VT was ended from intermittent capture
to complete stop in 5-10 seconds. One dog was provoked
transient couplet ventricular premature beats
immediately after ethanol injection. Neither spontaneous
VT nor ventricular fibrillation was observed. A small
coronary imaging was observed in a dog during trial
ablation. After position adjustment, successful ablation
was obtained.

Chronic Response of VT Focus to Chemical
Ablation
After acute ablation, 12 dogs were alive for
another 4 weeks. The VT could not be simulated in 10
dogs (complete effect 10/12, 83.3%). The other 2 dogs
could be simulated only intermittently (partial effect
2/12, 16.7%). Therefore the total effect rate was 100%
(12/12).

Figure 2. The simulated ventricular tachycardia was successfully ablated within 3 seconds (second arrow) by the first ethanol
injection (first arrow).
122
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Electrophysiological Study (Table 1)
The sinus rhythm circle length and ventricular
effective refractory period were not significantly
changed after chemical ablation (P>0.05). The induction
rate of new sustained and nonsustained VT was
respectively 5.6% (1/18) before ablation, 20% (3/15) in
30 minutes after ablation and 16.7% (2/12) in 4 weeks
after ablation.

Pathological Examination
After acute ablation, the color of the epicardium
above the implanted electrode became pale from its
surrounding flesh red. The pale lesion was 4±3 mm in
diameters with relative clear border. It was a little stiff
and dyskinesis. Under the microscopy, the myocardial
layer was evenly destroyed and looked like glassy
change, but the epicardium and endocardium
surrounding the ablation area were still integrity (Figure
3). Four weeks later, the ablation lesion focus was only
seen in the middle myocardial layer. Its color changed
into deep red and the lesion was completely fibrolitic
with normal outer epicardium and inner endocardium.
However, the border of the lesion was not so clear as
that in acute stage and, occasionally, normal myocardial
islands could be found in the chronic lesion.

limitations still exist. For example, transcatheter direct
current ablation procedure needs general anaesthesia.
Catheter disposition and serious complications are
common and there are delayed proarrhythmic actions.
In intracoronary chemical ablation, arrhythmic relative
coronary artery is hard to be located accurately. It does
not suit to ablate VT near larger coronary arteries and
without appropriate relative coronary artery. Preserved
heart function will be injured and new ventricular
tachyarrhythmia will be provoked during or after
ablation due to its artificial myocardial infarction. Radiofrequency catheter ablation now is one of the most privilege
interventional means in the radical cure of VT. However,
it is still not suitable to treat special VT such as their
foci or reentrant loops located in subepicardium,intraseptum, intramurum and larger area of subendocardium.
Theoretically, the percutaneous intramyocardial
chemical ablation approach has the advantages of: (1)
radical cure, (2) little myocardial injury, (3) suitable to
various intramural foci, (4) simpler procedure, (5)
repeatable use, and (6) fewer complications. But
actually, the above objectives are difficult to achieve
because of problems such as catheter design, chemical
agent selection, focus mapping, ablation manipulation
and experience accumulation.

Ideal Intramural Chemical Ablation Catheter

Discussion
Methodological Evaluation
At present, although many interventional
therapies of sustained ventricular tachycardia such as
transcatheter direct current ablation, intracoronary
chemical ablation and radiofrequency energy ablation
have their series clinical reports, their drawbacks and

Obviously, an ideal intramural chemical ablation
catheter should have the following characters. (1) It can
be easily operated by remote control. (2) It could be
clearly identified under the X-ray fluoroscopy. (3) It
can be used as both electrical and chemical mapping
catheter without catheter exchange. (4) Both chemical
and radiofrequency ablations can be conducted in
compliment to each other in one procedure. (5) The

Table 1. Electrophysiological study before and after chemical ablation
NSCL(ms)
VERP(ms)
VTs
VTn

Before ablation (n18)
302.7±57.4 (237-359)
176.3±74.6 (94-253)
1
0

30 minutes after ablation (n15)
294.1±79.5*(216-376)
184.9±96.2*(87-218)
1
2

4 weeks after ablation (n12)
315.8±43.7*(270-362)
168.6±84.3*(82-254)
0
2

* P>0.05 when compared with before ablation
NSCL: normal sinus circle length
VERP: ventricular effective refractory period
VTs: sustained VT
VTn: nonsustained VT
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(A)

(B)
Figure 3. Myocardial pathology after chemical ablation with 100% ethanol. (A) In
the ablation area, the myocardial layer was evenly destroyed and looked like glassy
change. The endocardium was still integrity. (B) The border between ablation target
and normal area was distinct.

injection volume and velocity of chemical agent can be
preciously selected. (6) Intramural electrical activity can
be mapped simultaneously with other electrograms by
microelectrodes installed in the injection needle. All
these characteristics are very important for safer and
more effective intramural chemical ablations. The
catheter used in this study obviously did not include all
above characters.
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Ventricular Tachycardia Model for Interventional Electrophysiology
The commonly used animal model of VT
includes: (1) coronary ligation and artificial myocardial
infarction; (2) chemical agent injection in coronary
artery, coronary vein, or peripheral veins to injure
myocardium and form irregular focus; (3) intramural
chemical agent injection to produce irregular excitement
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focus. The disadvantages of these models are: (1) low
VT production rate; (2) low reproducibility rate; (3) high
false positive and false negative rate; (4) limited
selection of VT original position, number, morphology
and type; (5) not suitable to evaluate the effect of
interventional treatment.
The new VT model in this study has the following
characters: (1) higher production rate and less material
waste; (2) higher selection and less randomization; (3)
more stable and reproducible; (4) various VTs can be
simulated; (5) can be used to both acute and chronic
experiment.

feasibility and effect of this chemical ablation procedure.
Otherwise, In this focal VT model, a sutured epicardial
pacing microelectrode was used. This electrode can be
used as a marker to induce the ablation and mapping
catheter manipulation under fluoroscopy. It will make
the ablation procedure easier than the natural VT
ablation. (2) The VT chemical ablation was tested only
in right ventricle. In the majority of patients with
ischemic VT, the sites of VT are usually originated from
the left ventricle. Therefore, further experiments are
needed to study the mapping and ablating effect of the
chemical ablation in the left ventricular originated VT.

Effect Evaluation of Intramural Chemical
Ablation

Summary

In this study, all 15 dogs were ablated
successfully. This result is obviously related to focus
mapping accuracy because the preimplanted
microelectrode could direct the precious and effective
endomyocardial mapping under fluoroscopy. Therefore,
if this technique is used in practice, accurate target area
mapping will be the key point.

Pathological Characters of Intramural Chemical
Ablation
After intramural chemical ablation, the
epicardium and endocardium structure is still intact.
Although it is not sure whether these structures
participate in long term proarrhythmic actions or not, it
is no doubt that they are very important to maintain the
regional systolic and diastolic functions. In addition,
the induction rate of the new VT is 20% in 30 minutes
after ablation and 16.7% in 4 weeks after ablation
respectively. They are significantly higher than that of
the preablation (5.6%). This strongly suggests that the
remained pathological changes after ablation are
proarrhythmogenic. It is supported by the evidences that
the border of the ablation lesion is not distinct from the
surrounding normal tissues and the alive myocardial
islands in region with chronic fibrous changes. This
action is due to the chemical agent selected or the
ablation lesion itself needs to be further evaluated.

Limitation
(1) The VT model used in this study is a focal
mechanism. It is very different in characters from the
VT originated from the previous myocardial infarction.
Therefore, an ischemic VT model is needed to test the

J HK Coll Cardiol, Vol 9

Percutaneous intramyocardial chemical ablation
conducted by a specially designed chemical ablation
catheter is feasible in the treatment of sustained focal
VT. The success rate could be 100% if the VT focus is
accurately mapped. No serious complications are found.
The ablation lesion is limited only in the myocardial
layer with intact epicardium and endocardium.
Therefore, the heart function is not influenced. New
VT induced after ablation suggests the potential long
term proarrhythmic action.

References
1. Josephson ME, Miller JM, Marchlinski FE, et al.
Nonpharmacologic therapy of ventricular tachycardia. Clin
Cardiol 1988;11(3, suppl 2):II17-21.
2. Aizawa Y, Murata M, Satah M, et al. Requirement of
nonpharmacologic intervention in treatment of reentrant
sustained ventricular tachycardia. Jpn Circ J 1990;54:1340.
3. Brugada P, de Swart H, Smeets JLRM, et al. Transcoronary
chemical ablation of ventricular tachycardia. Circulation 1989;
62:387.
4. Guhoke A, Schoen FJ, Zebede J, et al. Acute and chronic effects
of myocardial ablation using selective cardiac venous system
catheterization and ethanol injection. J Am Coll Cardiol 1992;
19:99A.
5. Lu CY, Liu XL, Jia GG, et al. An new model of experimental
ventricular tachycardia. Chinese J of Cardiac Pacing and
Electrophysiology 1994;8:213.
6. Brugada P. Standard diagnostic programmed electrical
stimulation protocols in patients with paroxysmal recurrent
tachycardia. PACE 1984;7:1121.
7. Lu CY, Song J, Pu JL, et al. Diagnostic value of quantitative
mapping of atrial activation for the cardiac accessory pathway
location. Chin Med J 1991;104:36.

July 2001

125

